Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis

Journal of Medical Economics

Volumn 17, Issue 5, 2014, Pages 320-325

  Santoleri, Fiorenzo ^a   Sorice, Paola ^a   Lasala, Ruggero ^a   Rizzo, Rosa Carmela ^a   Costantini, Alberto ^a  

^a General Hospital of Pescara Hospital Pharmacy   (Italy)

Author keywords

Medication adherence; Prescribed daily dose; Received daily dose; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GENERAL HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOLOGICAL PARAMETERS; PRESCRIBED DALIY DOSE; PRESCRIPTION; RECEIVED DAILY DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; ECONOMICS; KAPLAN MEIER METHOD; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84924924929     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.902844     Document Type: Article

References (27)

1. Fattahi MJ, Mirshafiey A. Prostaglandins and rheumatoid arthritis. Arthritis 2012;2012:239-310
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
3. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72
4. van de Sande MG, de Hair MJ, Schuller Y, et al. The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. PLoS One 2012;7:e36668
5. Mahboob UR, Jacqui B, Mittie KD, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011;70:1631-40
6. Schett G, Coates LC, Ash ZR, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011;13(Suppl 1):S4
7. Papp K, Ho V, Teixeira HD, et al. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. J Eur Acad Dermatol Venereol 2012;26:1007-13
8. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10). doi:10.3310/hta15100
9. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 2011;68:795-806
10. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-Analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794
11. Marchesoni A, Zaccara E, Gorla R, et al. TNF-Alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46
12. Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis-A study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011;30:1447-54
13. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
14. Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 2012;15:332-9
15. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 2012;8:337-51
16. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011;33:901-13
17. Granger BB, Bosworth HB. Medication adherence: emerging use of technology. Curr Opin Cardiol 2011;26:279-87
18. Noussa Yao J, Séroussi B, Bouaud J. Computing the compliance of physician drug orders with guidelines using an OWL2 reasoner and standard drug resources. Stud Health Technol Inform 2011;169:512-6
19. Punzi L, Matucci Cerinic M, Cantini F, et al. Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo 2011; 63:18-28
20. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization, 2003
21. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
22. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14
23. Jobanputra P. A clinician's critique of rheumatoid arthritis health economic models. Rheumatology (Oxford) 2011;50(4 Suppl):iv48-iv52
24. Welton NJ, Madan J, Ades AE. Are head-to-haed trials biologics needed? The role of value of informations method in arthritis research. Rheumatology (Oxford) 2011;50(4 Suppl):iv19-iv25
25. Van Vollenhoven RF, Severens JL. Observational studies: a valuable source for data on the true value of RA therapies. Clin Rheumatol 2011;30(1 Suppl): S19-24
26. Tosh J, Brennan A, Wailoo A, et al. The Sheffield rheumatoid arthritis health economic model. Rheumatology (Oxford) 2011;50(4 Suppl): iv26-31
27. Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29:234-48